A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma

References

• Gramatzki D, Roth P, Felsberg J, et al. Chemotherapy for spinal gliomas in adults: a retrospective study. Neuro Oncol. 2018;20(Suppl 6):vi240. doi:10.1093/neuonc/noy148.993
   Google Scholar
• Fujiwara Y, Manabe H, Izumi B, et al. Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. Eur Spine J. 2018;27(Suppl 3):421–425. doi:10.1007/s00586-017-5413-z
   PubMedGoogle Scholar
• Chaskis E, Minichini V, Luce S, et al. [Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: our experience]. Neurochirurgie. 2017;63(4):297–301. Romanian. doi:10.1016/j.neuchi.2017.05.002
   PubMed Web of Science ®Google Scholar
• Velz J, Neidert MC, Struckmann K, et al. A rare case of diffuse midline glioma, H3 K27M mutant, of the spinal cord mimicking meningitis. SN Comprehen Clin Med. 2019;1(1):15–19. doi:10.1007/s42399-018-0007-6
   Google Scholar
• Teng YD, Abd-El-Barr M, Wang L, et al. Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies. Exp Neurol. 2019;311:135–147. doi:10.1016/j.expneurol.2018.09.010
   PubMed Web of Science ®Google Scholar
• Prelaj A, Rebuzzi SE, Caffarena G, et al. Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature. Oncol Lett. 2018;15(5):6641–6647.
   PubMed Web of Science ®Google Scholar
• Wei J, Yang G, Hao X, et al. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. Eur Radiol. 2018;29(2):877–888.
   PubMed Web of Science ®Google Scholar
• Choi SH, Yoon HI, Yi S, et al. Treatment outcomes of radiotherapy for primary spinal cord glioma. Strahlenther Onkol. 2019;195(2):164–174. doi:10.1007/s00066-018-1366-3
   PubMed Web of Science ®Google Scholar
• Diaz-Aguilar D, ReFaey K, Clifton W, et al. Prognostic factors and survival in low grade gliomas of the spinal cord: a population-based analysis from 2006 to 2012. J Clin Neurosci. 2019;61:14–21. doi:10.1016/j.jocn.2018.11.025
   PubMed Web of Science ®Google Scholar
• Rovin RA, Winn R. Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report. J Neurosurg Spine. 2007;6(5):447–450. doi:10.3171/spi.2007.6.5.447
   PubMed Web of Science ®Google Scholar
• Tseng HM, Kuo LT, Lien HC, et al. Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. Anticancer Drugs. 2010;21(10):963–967. doi:10.1097/CAD.0b013e32833f2a09
   PubMed Web of Science ®Google Scholar
• Wang GH, Yang J, Wang ZC. Surgical treatment strategy and efficacy of intramedullary ependymoma of spinal cord. Chin J Minimal Invasive Neurosurg. 2010;15(3):99–101.
   Google Scholar
• Kim WH, Yoon SH, Kim CY, et al. Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review. J Neurooncol. 2011;101(2):247–254. doi:10.1007/s11060-010-0249-y
   PubMed Web of Science ®Google Scholar
• Raco A, Piccirilli M, Land A, et al. High-grade intramedullary astrocytomas: 30 years experience at the Neurosurgery Department of the University of Rome“Sapienza”. J Neurosurg Spine. 2010;12:144–153. doi:10.3171/2009.6.SPINE08910
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Mondesire-Crump I, Gavrilovic IT. Temozolomide or bevacizumab for spinal cord high-grade gliomas. J Neurooncol. 2012;109(2):385–389. doi:10.1007/s11060-012-0905-5
   PubMed Web of Science ®Google Scholar
• Schellinger KA, Propp JM, Villano JL, McCarthy BJ. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol. 2008;87(2):173–179. doi:10.1007/s11060-007-9507-z
   PubMed Web of Science ®Google Scholar
• Eroes CA, Zausinger S, Kreth FW, et al. Intramedullary low grade astrocytoma and ependymoma.Surgical results and predicting factors for clinical outcome. Acta Neurochir. 2010;152:611–618. doi:10.1007/s00701-009-0577-x
   PubMed Web of Science ®Google Scholar
• Benes V, Barsa P, Benes V, Suchomel P. Prognostic factors in intramedullary astrocytomas: a literature review. Eur Spine J. 2009;18(10):1397–1422. doi:10.1007/s00586-009-1076-8
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Temozolomide for recurrent low-grade spinal cord gliomas in adults. Cancer. 2008;113(8):1019–1024. doi:10.1002/cncr.23677
   PubMedGoogle Scholar
• Chamoun RB, Alaraj AM, Al Kutoubi AO, et al. Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. Acta Neurochir (Wien). 2006;148(2):175–179. doi:10.1007/s00701-005-0694-0
   PubMed Web of Science ®Google Scholar
• Sala F, Palandri G, Basso E, et al. Motor evoked potential monitoring improves outcome after surgery for intramedullary spinal cord tumors: a historical control study. Neurosurgery. 2006;58:1129–1143. doi:10.1227/01.NEU.0000215948.97195.58
   PubMed Web of Science ®Google Scholar
• Nehru GA, Pai R, Samuel P, et al. Status of O6-methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. Neurol India. 2012;60(5):481–486. doi:10.4103/0028-3886.103190
   PubMed Web of Science ®Google Scholar
• Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One. 2001;52(1):85–94.
   Google Scholar
• Kim MS, Chung CK, Choe G, et al. Intramedullary spinal cord astrocytoma in adults: postoperative outcome. J Neurooncol. 2001;52(1):85–94. doi:10.1023/A:1010680924975
   PubMed Web of Science ®Google Scholar
• Senhaji Mouhri Z, Goodfellow E, Jean-Claude B. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. BMC Cancer. 2017;17(1):540. doi:10.1186/s12885-017-3504-1
   PubMedGoogle Scholar
• Chang UK, Choe WJ, Chung SK, et al. Surgical outcome and prognostic factors of spinal intramedullary ependymomas in adults. J Neurooncol. 2002;57(2):133–139. doi:10.1023/A:1015789009058
   PubMed Web of Science ®Google Scholar
• Yu LS, Yu HX, Qu BH, Zhang DY. MR diagnosis and clinical stage observation of 55 cases of radioactive myelopathy. Chin J Pract Nervous Dis. 2009;12(14):49–50.
   Google Scholar
• Xu XT, Li L, Zhou JY, et al. Retrospective analysis for prognostic factors of primary spinal cord glioma treated with radiation therapy. Tumour. 2005;25(3):257–259.
   Google Scholar
• Shen D, Yang QY, Chen ZP. Research progress of temozolomide in malignant glioma chemotherapy. Chin J Neuro Oncol. 2010;8(4):271–276.
   Google Scholar
• Xu HS, Zhang JY, Yue WY, et al. Relationship between MGMT expression in gliomas and in vitro their sensitivity to drug as well as its clinical significance. Chin J Clin Neurosurg. 2007;12(5):263–266.
   Google Scholar
• Qiu ZK, Feng BH, Chen ZP. Advances in the expression of MGMT in glioma. Chin J Neuro Oncol. 2010;8(1):44–50.
   Google Scholar